News

CellAura User Group Workshop

Mon 9 Jan 2012

CellAura Technologies invites its customers, current users of fluorescent ligands, and those interesting in learning more about the uses of fluorescent ligands, to attend the Inaugural Fluorescent Ligands Workshop to be held at BioCity on 25th April 2012.

The meeting will be Chaired by Professor Steve Hill from the University of Nottingham.

The provisional speaker line-up includes:

Dr Leigh Stoddart (University of Nottingham)
Dr Lauren May   (Monash University, Australia)
Dr Sergei Kopanchuk (University of Tartu, Estonia)
Dr Steve Briddon (University of Nottingham)
Another speaker (to be confirmed)

There will also be selected assay and instrument demonstrations running during the Workshop.
Transport between the BPS venue in Leicester and BioCity for the workshop will be provided by CellAura.

Information about registering for the Workshop is provided on the CellAura Events page.
Further news about the Speaker presentations and Workshop demonstrations will be posted on the CellAura News page in due course.

 

 

CellAura launches Fluorescent Ligands discussion group on LinkedIn

Fri 18 Nov 2011

CellAura has launched a discussion group on LinkedIn titled: Fluorescent Ligands - enabling novel GPCR Biology and Drug Discovery.

The purpose of the group is to provide a forum for discussions promoting the novel thinking that is emerging around the use of fluorescent GPCR ligands for research and drug discovery.

The group is an exclusive members-only global scientific forum for professionals from Pharma, Biotech and Academia.

If you would like to join the forum, please use your LinkedIn profile to send us a request to join.

 

CellAura launches new beta3 adrenoceptor agonist fluorescent ligand

Wed 1 Jun 2011

 

CellAura has added a new fluorescent adrenoceptor ligand to its product catalogue.  
The new fluorescent ligand has been developed for the beta-adrenoceptor family based on the beta-blocker, carazolol. The new fluorescent (S)-carazolol-derivative is a partial agonist at β3 adrenoceptors, and acts as an antagonist at β1 and β2 adrenoceptors  The new product is now available as a standard catalogue item.
 
Further product development is expected to include new serotonergic receptor ligands and to provide full coverage of the muscarinic receptor family. These additional products will be launched over the forthcoming months.

 

CellAura to showcase Fluorescent Ligand Perfusion Technology design concept at ELRIG Cell-Based Screening meeting

Fri 25 Feb 2011

The ELRIG Advances in Cell Based Screening Technologies meeting at Hinxton Hall, Cambridge, UK, on 15th March 2011, is a free-to-register event that will present the latest cutting edge detection technologies and biological techniques transitioning into screening labs.

CellAura Technologies will be attending the ELRIG Cell Based Screening meeting to promote its expanding range of fluorescent GPCR ligands for drug discovery and life science research. It will also be show-casing its design concept for a Confocal Perfusion System to be mounted onto a range of confocal microscope platforms. Please register for the meeting (click here) and visit our booth to discuss your interest in our reagents and perfusion technology.

 

CellAura signs license with University of Nottingham to access Confocal Perfusion System for measuring fluorescent ligand binding kinetics

Tue 4 Jan 2011

The University of Nottingham has developed a novel perfusion system mounted onto a confocal fluorescence microscope that allows the binding of fluorescent ligands to GPCRs expressed on live cells to be observed in real-time. Quantification of ligand binding and dissociation from individual cells under continuous perfusion flow allows the kinetics of ligand-receptor interactions to be determined. This is probably the first technology to be able to determine ligand binding kinetics on a single live cell. 

CellAura has signed a license with the University of Nottingham to be able to access the novel perfusion system, which uses CellAura’s fluorescent ligands as its principal reagent. It is CellAura’s intention to commercialise the perfusion technology to provide an instrument platform on which its reagents can be readily used to measure ligand affinity, binding duration, and allosteric effects of drug candidates to alter fluorescent ligand binding and dissociation rates.

 

CellAura moves to new laboratories

Tue 21 Dec 2010

CellAura has completed the move of its chemistry and office facilities into new expansive premises in the Stewart Adams Building on the BioCity site in Nottingham.

The new facilities comprise a significantly larger, well-equipped chemistry laboratory to accomodate CellAura's growing team of synthetic chemists, with an adjacent cell biology / pharmacology laboratory for product validation. The move brings together all of CellAura's R&D, Production and Product Validation functions into a single operationally-streamlined laboratory and office unit. 

 

CellAura releases beta-test version of High Content image analysis software

Wed 24 Nov 2010

CellAura acknowledges that the bottleneck in High Content Analysis is not the generation of high resolution images of fluorescently labelled cells and tissues, but is often the off-line analysis of the image collection to determine the effect(s) of a particular treatment.

To address this bottleneck, CellAura have developed analysis macros for the NIH Image J image analysis software package that are suitable for quantifying the binding of CellAura’s fluorescent ligands. These analysis macros are available as beta-test versions incorporated into the Image J software for free download and testing. The analysis modules are also available as standalone free downloads for incorporation into existing Image J installations. These downloads are available from our website by going to the Image Analysis section.

 

CellAura adds improved 5-HT1A antagonist fluorescent ligand to its catalogue

Wed 22 Sep 2010

CellAura has added an improved 5-HT1A antagonist to its fluorescent ligand catalogue. This improved ligand has higher affinity at the 5-HT1A receptor, with a logKD of -8.75.

The selectivity of this ligand has also been determined at other 5-HT receptors; with a logKD of -6.34 at 5-HT2A, the improved ligand is more than 250-fold selective for 5-HT1A.